Details

Autor(en) / Beteiligte

• Pennathur, Sridhar
• Haller, Aurelia A
• MacPhail, Mia
• Rizzi, Tom
• Kaderi, Sepideh
• Fernandes, Fiona
• Bicha, Leenas
• Schickli, Jeanne H
• Tang, Roderick S
• Chen, Wendy
• Nguyen, Nick
• Mathie, Sharon
• Mehta, Hersh
• Coelingh, Kathleen L

Titel

Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys

Ist Teil von

• Journal of general virology, 2003-12, Vol.84 (12), p.3253-3261

Ort / Verlag

England: Soc General Microbiol

Erscheinungsjahr

2003

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• MedImmune Vaccines Inc., 297 North Bernardo Avenue, Mountain View, CA 94043, USA Correspondence Sridhar Pennathur pennathurs{at}medimmune.com Restricted replication in the respiratory tract of rhesus monkeys is an intrinsic property of bovine parainfluenza virus type 3 (bPIV-3) strains. This host range phenotype of bPIV-3 has been utilized as a marker to evaluate the attenuation of bPIV-3 vaccines for human use. Two safety, immunogenicity and efficacy studies in primates evaluated and compared three human parainfluenza virus type 3 (hPIV-3) vaccine candidates: biologically derived bPIV-3, a plasmid-derived bPIV-3 (r-bPIV-3) and a chimeric bovine/human PIV-3 (b/hPIV-3). These studies also examined the feasibility of substituting Vero cells, cultured in the presence or absence of foetal bovine serum, for foetal rhesus lung-2 (FRhL-2) cells as the tissue culture substrate for the production of bPIV-3 vaccine. The results demonstrated that (i) Vero cell-produced bPIV-3 was as attenuated, immunogenic and efficacious as bPIV-3 vaccine grown in FRhL-2 cells, (ii) plasmid-derived bPIV-3 was as attenuated, immunogenic and efficacious as the biologically derived bPIV-3 and (iii) the b/hPIV-3 chimera displayed an intermediate attenuation phenotype and protected animals completely from hPIV-3 challenge. These results support the use of bPIV-3 vaccines propagated in Vero cells in human clinical trials and the use of b/hPIV-3 as a virus vaccine vector to express foreign viral antigens. S. Pennathur and A. A. Haller contributed equally to this work. Published ahead of print on 17 September 2003 as DOI 10.1099/vir.0.19522-0.